Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 3/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8764230 | 0.87 | MEN1 (0.64) | MEN1KMT2AMMP9MMP13CYP2A6 | |
| SCHEMBL19510650 | 0.86 | TAAR1 (0.46) | MEN1KMT2ATAAR1HTR2AMAOB | |
| SCHEMBL24510654 | 0.83 | TAAR1 (0.43) | MEN1KMT2ATAAR1HTR2AMAOB | |
| SCHEMBL7711099 | 0.81 | MEN1 (0.52) | MEN1KMT2ATAAR1HTR2AMMP9 | |
| SCHEMBL8763175 | 0.80 | MEN1 (0.56) | MEN1KMT2AMMP9MMP13CYP1A1 | |
| SCHEMBL9552869 | 0.80 | KMT2A (0.56) | MEN1KMT2AMAOBMMP9MMP13 | |
| SCHEMBL7390958 | 0.79 | RAB9A (0.42) | MEN1KMT2ATAAR1HTR2A | |
| SCHEMBL12964909 | 0.76 | PYCR1 (0.53) | TAAR1HTR2AMAOBCYP2A6IDO1 | |
| SCHEMBL450038 | 0.76 | ESR1 (0.59) | MEN1KMT2ATAAR1CYP1A2 | |
| SCHEMBL18245397 | 0.76 | TAAR1 (0.50) | TAAR1HTR2AMAOBCYP2A6IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694513-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2014-02-12 | — | — | EP | claimed |
| WO-2012131633-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-10-04 | — | — | WO | claimed |
| WO-2025122555-A1 | S1P 1 RECEPTOR AGONISTS AND USES THEREOF | VALO HEALTH, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025120242-A1 | CHIMERIC RADIOPHARMACEUTICALS TARGETING THE PROTON SENSING RECEPTOR GPR4 | AMPHILIX AG (CH) | 2025-06-12 | — | — | WO | disclosed |
| CN-115368275-B | Cyanostyrene-based aggregation-induced emission material, and preparation method and application thereof | 豫章师范学院 | 2024-08-13 | — | — | CN | disclosed |
| CN-116964034-A | Heterocyclic ring P2Y 14 Receptor antagonists | 美国卫生和人力服务部 | 2023-10-27 | — | — | CN | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-111196770-B | Simple preparation method of bromfenac sodium | 新发药业有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-111574438-B | Red/near-infrared AIE probe, preparation method thereof and application thereof in detection of Abeta aggregates and fibrotic plaques thereof | 华东理工大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-111574438-A | Red/near-infrared AIE probe, preparation method thereof and application thereof in detection of Abeta aggregates and fibrotic plaques thereof | 华东理工大学 | 2020-08-25 | — | — | CN | disclosed |
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-6166028-A | Diaminopuridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000034268-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034238-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034261-A2 | HETEROCYCLIC CARBOXAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A SUBSTITUTED PHENYLENEDIAMINE GROUP | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034260-A2 | ALPHA-METHYLBENZYL-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING A PHENYLENEDIAMINE GROUP | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034269-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034237-A2 | ACETAMIDE AND SUBSTITUTED ACETAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034258-A2 | HETEROCYCLIC CARBOXAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES CONTAINING PHENYLENEDIAMINE GROUP | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| US-4226878-A | ANTIINFLAMMATORY, HYPOTENSIVES, ANTIHISTAMINES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1980-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | MEN1 4681/4885KMT2A 4093/4885TAAR1 4696/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | MEN1 4681/4885KMT2A 4093/4885TAAR1 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.